Development of a pan-botulinum neurotoxin medical countermeasure
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50120C00198
- Awardee
-
Mapp Biopharmaceutical, Inc. UEI M9V9QTHR1H28
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $16,413,163
Award facts
- Opportunity
-
- BARDABAA18100SOL0000 Solicitation number
- Development of a Pan-Botulinum Neurotoxin Medical Countermeasure Award Notice · Posted Oct 6, 2020
- Contract value 100% obligated
- $16,413,163.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- San Diego, CA 92121, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $109,456 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $718,194 | |
| Exercise an Option | $1,498,312 | |
| Other Administrative Action | $0 | |
| Change Order | $4,450,745 | |
| Exercise an Option | $4,704,563 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $444,289 | |
| Original award | $4,487,604 |
Show all 14
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a $16.41 million Cost Plus Fixed Fee definitive contract to Mapp Biopharmaceutical, Inc. for the development of a pan-botulinum neurotoxin medical countermeasure. The contract was awarded on September 30, 2020, with an ultimate completion date of June 30, 2026, and will be performed in San Diego, California. This award carries no set-aside designation and reflects Mapp's established capability as a critical federal partner in medical countermeasure development. The contract represents part of ASPR's broader mission to develop medical interventions against biological threats and emerging health challenges.
Mapp Biopharmaceutical, a San Diego-based biotechnology company specializing in antibody-based therapeutics, has demonstrated substantial federal contracting experience with a portfolio exceeding $1.2 billion in awards. This botulinum neurotoxin countermeasure contract aligns with the company's core competency in developing immunotherapies against infectious diseases and biological threats. However, it should be noted that this contract was subject to a termination for convenience notice issued on February 26, 2025, as part of the Presidential Cost Savings Initiative, indicating the development effort was discontinued prior to the originally scheduled completion date.
Quick answers
Who was awarded contract 75A50120C00198?
75A50120C00198 was awarded to Mapp Biopharmaceutical, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2020.
How much is contract 75A50120C00198 worth?
The government has obligated $16,413,163 on 75A50120C00198.
Was contract 75A50120C00198 competed?
The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award